Evans D W

Evans D W, Hosking S L, Gherghel D, Bartlett J D

Brimonidine therapy in new glaucoma patients improved contrast sensitivity, unlike timolol, suggesting potential neuroprotective benefits beyond IOP reduction.

Hosking S L, Evans D W, Embleton S J, Houde B, Amos J F, Bartlett J D

Mild hypercapnia acutely reduced contrast sensitivity in untreated glaucoma patients, suggesting these patients are more vulnerable to CO2-induced visual impairment, potentially indicating neuronal damage.

Evans D W, Harris A, Garrett M, Chung H S, Kagemann L

Glaucoma patients exhibit impaired central retinal artery blood flow regulation during posture changes, unlike healthy individuals. This suggests faulty ocular autoregulation may contribute to glaucoma pathology.

Chung H S, Harris A, Evans D W, Kagemann L, Garzozi H J, Martin B

Glaucoma involves vascular deficits, potentially linked to IOP and impaired autoregulation, impacting optic nerve health. Improving ocular blood flow may offer a therapeutic strategy.

Evans D W, Harris A, Chung H S, Cantor L B, Garzozi H J

Long-term beta-blocker therapy for POAG significantly improved altered retrobulbar blood flow (CRA/SPCA resistance), suggesting a positive impact on ocular hemodynamics beyond just IOP reduction.

Harris A, Evans D W, Cantor L B, Martin B

Oral nifedipine in normal-tension glaucoma showed inconsistent visual and hemodynamic benefits, with improvements linked to better retrobulbar perfusion in some patients, suggesting variable clinical utility.

Pomerance G N, Evans D W

Glaucoma patients on beta-blockers showed improved contrast sensitivity, and the CSV-1000 reliably detected these clinically significant visual function changes, supporting its use for monitoring.